WEBVTT

00:00:02.200 --> 00:00:05.120
Repair begins with a biological response.

00:00:05.940 --> 00:00:08.240
Establishing that a treatment improves
recovery

00:00:08.240 --> 00:00:10.560
takes a different kind of evidence.

00:00:11.480 --> 00:00:16.460
BPC-157 is an experimental peptide

00:00:16.460 --> 00:00:18.840
made of fifteen amino acids.

00:00:19.920 --> 00:00:22.360
Laboratory and animal studies can suggest
mechanisms.

00:00:23.480 --> 00:00:26.840
They cannot, by themselves, establish that

00:00:26.840 --> 00:00:29.420
an injured person will recover faster.

00:00:29.880 --> 00:00:33.580
In a 2021 report, Lee and Padgett reviewed

00:00:33.580 --> 00:00:37.780
seventeen knee-pain patients and reached
sixteen for follow-up.

00:00:38.440 --> 00:00:41.940
Twelve had received BPC-157 alone;

00:00:42.700 --> 00:00:45.120
eleven reported significant pain
improvement.

00:00:46.020 --> 00:00:49.200
Four others received it with thymosin beta
four.

00:00:49.940 --> 00:00:53.100
Those reports came from an uncontrolled
study.

00:00:53.700 --> 00:00:58.240
Less pain does not demonstrate that tendon
or cartilage has healed.

00:00:58.680 --> 00:01:02.500
The digestive tract is another major
research focus.

00:01:03.220 --> 00:01:09.560
In rat experiments, BPC-157 reduced
experimentally induced stomach

00:01:09.560 --> 00:01:13.100
ulcers and improved healing in some fistula
models.

00:01:13.880 --> 00:01:16.220
These are encouraging animal findings.

00:01:17.020 --> 00:01:20.380
Human evidence includes a 2005 ulcerative-
colitis

00:01:20.380 --> 00:01:23.140
trial reported in a conference abstract.

00:01:23.960 --> 00:01:26.180
Fifty-three people were randomized.

00:01:26.820 --> 00:01:29.900
Disease-activity scores improved in both
groups.

00:01:30.500 --> 00:01:32.600
The between-group estimate was too
uncertain

00:01:32.600 --> 00:01:34.860
to establish a benefit over placebo.

00:01:35.740 --> 00:01:39.860
The FDA concluded that the available data
were

00:01:39.860 --> 00:01:43.240
inadequate to establish efficacy and safety
for that use.

00:01:44.100 --> 00:01:47.000
Gastrointestinal promise is a research
lead;

00:01:47.580 --> 00:01:50.800
reliable treatment success in people
remains unproven.

00:01:51.640 --> 00:01:55.480
The next step is a defined preparation, a
fair comparison,

00:01:55.480 --> 00:02:00.560
and consistent measures of symptoms,
function, and tissue change.

00:02:01.380 --> 00:02:04.620
Safety also needs adequate follow-up.

00:02:04.980 --> 00:02:06.940
World Peptide Foundation.

00:02:07.600 --> 00:02:09.140
Peptides in 2.

00:02:09.460 --> 00:02:10.860
Every experience matters.